PE20040193A1 - INJECTABLE BIPHOSPHONATE FORMULATIONS - Google Patents
INJECTABLE BIPHOSPHONATE FORMULATIONSInfo
- Publication number
- PE20040193A1 PE20040193A1 PE2003000440A PE2003000440A PE20040193A1 PE 20040193 A1 PE20040193 A1 PE 20040193A1 PE 2003000440 A PE2003000440 A PE 2003000440A PE 2003000440 A PE2003000440 A PE 2003000440A PE 20040193 A1 PE20040193 A1 PE 20040193A1
- Authority
- PE
- Peru
- Prior art keywords
- bisodium
- acid
- divaldonate
- biphosphonate
- injectable
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000002253 acid Substances 0.000 abstract 3
- 208000010191 Osteitis Deformans Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000027868 Paget disease Diseases 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- HJKBJIYDJLVSAO-UHFFFAOYSA-L clodronic acid disodium salt Chemical compound [Na+].[Na+].OP([O-])(=O)C(Cl)(Cl)P(O)([O-])=O HJKBJIYDJLVSAO-UHFFFAOYSA-L 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 159000000011 group IA salts Chemical class 0.000 abstract 1
- 238000007918 intramuscular administration Methods 0.000 abstract 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 abstract 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 abstract 1
- 208000027202 mammary Paget disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- CAKRAHQRJGUPIG-UHFFFAOYSA-M sodium;[4-azaniumyl-1-hydroxy-1-[hydroxy(oxido)phosphoryl]butyl]-hydroxyphosphinate Chemical compound [Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O CAKRAHQRJGUPIG-UHFFFAOYSA-M 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA FORMULACION FARMACEUTICA QUE COMPRENDE: a)UNA SAL ALCALINA DE UN ACIDO BIFOSFONICO FARMACOLOGICAMENTE ACTIVO DONDE EL ACIDO BIFOSFONICO SE SELECCIONA DEL ALENDRONATO MONOSODICO, CLODRONATO BISODICO NERIDRONATO SODICO O PAMIDRONATO BISODICO DONDE LA CONCENTRACION DE DICHA SAL ALCALINA SE ENCUENTRA EN EL INTERVALO DE 1 mg/ml A 200 mg/ml; Y b)CLORHIDRATO DE LIDOCAINA EN UNA CONCENTRACION EN EL INTERVALO DE 0,5% Y 2,0% (P/V). DICHA FORMULACION ES PARTICULARMENTE APROPIADA PARA LA ADMINISTRACION POR VIA INTRAMUSCULAR PARA EL TRATAMIENTO DE PATOLOGIAS DEL SISTEMA OSEO COMO OSTEOPOROSIS, ENFERMEDAD DE PAGET, HIPERTIROIDISMO, ENTRE OTRASIT REFERS TO A PHARMACEUTICAL FORMULATION THAT INCLUDES: a) AN ALKALINE SALT OF A PHARMACOLOGICALLY ACTIVE BIPHOSPHONIC ACID WHERE THE BIPHOSPHONIC ACID IS SELECTED FROM THE MONOSODIUM ALENDRONATE, BISODIUM CHLODRONATE SODIUM ACIDONIUM DUENTHALDONIUM DALCENTHYL DIVALDONATE BISODIUM NERIDHYCODONIUM SALT DIVALDONATE IN SALTDICHRONATE BISODIUM NERIDHYCODONATE SODONIUM SALTED BISODIUM ACID 1mg / ml to 200mg / ml; AND b) LIDOCAINE HYDROCHLORIDE IN A CONCENTRATION IN THE INTERVAL OF 0.5% AND 2.0% (P / V). SUCH FORMULATION IS PARTICULARLY APPROPRIATE FOR ADMINISTRATION VIA INTRAMUSCULAR ROUTE FOR THE TREATMENT OF PATHOLOGIES OF THE BONE SYSTEM SUCH AS OSTEOPOROSIS, PAGET'S DISEASE, HYPERTHROIDISM, AMONG OTHERS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2002TO000406A ITTO20020406A1 (en) | 2002-05-13 | 2002-05-13 | FORMULATIONS OF BISPHOSPHONATES FOR INJECTABLE USE. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20040193A1 true PE20040193A1 (en) | 2004-05-31 |
Family
ID=27639074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000440A PE20040193A1 (en) | 2002-05-13 | 2003-05-06 | INJECTABLE BIPHOSPHONATE FORMULATIONS |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR040001A1 (en) |
| AU (1) | AU2003240225A1 (en) |
| IT (1) | ITTO20020406A1 (en) |
| PE (1) | PE20040193A1 (en) |
| WO (1) | WO2003094925A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006012700A1 (en) * | 2004-08-04 | 2006-02-09 | Team Health Pty Ltd | Method of treatment |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1187828B (en) * | 1985-05-24 | 1987-12-23 | Gentili Ist Spa | PHARMACEUTICAL COMPOSITION BASED ON DIPHOSPHONATES FOR THE TREATMENT OF ARETROSIS |
| US5462932A (en) * | 1994-05-17 | 1995-10-31 | Merck & Co., Inc. | Oral liquid alendronate formulations |
| IT1296495B1 (en) * | 1997-11-21 | 1999-06-25 | Prodotti Antibiotici Spa | USE OF BISPHOSPHONATES IN THE PREPARATION OF PHARMACEUTICAL FORMS FOR INTRAMUSCULAR ADMINISTRATION |
| US6677320B2 (en) * | 2000-01-20 | 2004-01-13 | Hoffmann-La Roches Inc. | Parenteral bisphosphonate composition with improved local tolerance |
| EP1136069A1 (en) * | 2000-03-21 | 2001-09-26 | SPA SOCIETA' PRODOTTI ANTIBIOTICI S.p.A. | Pharmaceutical compositions containing clodronates for high local tolerance intramuscular administration |
-
2002
- 2002-05-13 IT IT2002TO000406A patent/ITTO20020406A1/en unknown
-
2003
- 2003-05-06 PE PE2003000440A patent/PE20040193A1/en not_active Application Discontinuation
- 2003-05-12 WO PCT/EP2003/004934 patent/WO2003094925A1/en not_active Ceased
- 2003-05-12 AU AU2003240225A patent/AU2003240225A1/en not_active Abandoned
- 2003-05-12 AR ARP030101639A patent/AR040001A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003240225A1 (en) | 2003-11-11 |
| WO2003094925A1 (en) | 2003-11-20 |
| AR040001A1 (en) | 2005-03-09 |
| ITTO20020406A1 (en) | 2003-11-13 |
| ITTO20020406A0 (en) | 2002-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2244831T5 (en) | Use of panthenol and / or pantothenic acid and hyaluronic acid and / or hyaluronate for the production of a pharmaceutical composition for ophthalmological application | |
| RU2008138266A (en) | COMPOSITIONS FOR Parenteral administration of drugs AND THEIR USE | |
| NO20081889L (en) | Solid vaccine formulation | |
| ATE538774T1 (en) | PHARMACEUTICAL FORMULATIONS AND METHODS FOR TREATING RESPIRATORY INFECTIONS | |
| DOP2006000192A (en) | IMPROVED IBANDRONATE FORMULATIONS | |
| AR046773A1 (en) | PHARMACEUTICAL FORMULATIONS OF BISPHOSPHONATES | |
| PE20081150A1 (en) | DIPETHYLPEPTIDASE INHIBITORS | |
| US20160030572A1 (en) | Liquid formulations | |
| ES2190244T3 (en) | USE OF THE PARTIROID HORMONE CONSTITUTED BY A SEQUENCE OF AMINO ACIDS 1-34 OF THE HUMAN PARTIROID HORMONE TO REDUCE THE RISK OF VERTEBRAL AND NON-VERTEBRAL BONE FRACTURES. | |
| CY1106482T1 (en) | PHARMACEUTICAL PARENTEPIC COMPOSITION COMPRISING A DIPHOSPHONIC | |
| RU2011122629A (en) | AQUATIC COMPOSITION CONTAINING A FOLICULOSTIMULATING HORMONE | |
| CO5390076A1 (en) | PHARMACEUTICAL COMPOSITIONS | |
| CO6180498A2 (en) | A COMPOSITION OF SUSTAINED RELEASE THAT INCLUDES A PHYSIOLOGICALLY ACTIVE PEPTIDE SOLUBLE IN WATER DISPERSED UNIFORMLY IN A MICROCAPSULA | |
| BR0008509A (en) | Stabilized oral pharmaceutical composition containing iodide and iodate and method | |
| LU91281I2 (en) | Preotact-parathyroid hormone | |
| ECSP044961A (en) | ACID N- (5-CHLOROSALICILOIL) -8-AMINOCAPRILICO AS AN ORAL SUPPLY AGENT FOR PARTIROID HORMONE FRAGMENTS | |
| EA200900095A1 (en) | DOSAGE FORMS OF BIPHOSPHONATES FOR INHALATION AND METHODS OF THEIR USE | |
| ATE427737T1 (en) | MICROEMULSIONS OF RETINOIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | |
| PE20040193A1 (en) | INJECTABLE BIPHOSPHONATE FORMULATIONS | |
| PE20050189A1 (en) | COMPOSITIONS INCLUDING QUINOLONCARBOXYL ACID DERIVATIVES FOR LOCAL ADMINISTRATION | |
| ES2262145T3 (en) | ANABOLIC COMPOSITION FOR THE OSEA MASS THAT INCLUDES OLPADRONATE. | |
| ES2251226T3 (en) | USE OF BISPHOSPHONIC ACID DERIVATIVES FOR THE PREPARATION OF A MEDICINAL PRODUCT INTENDED FOR THE PROCESSING OF THE LAKE. | |
| AR022462A1 (en) | USE OF AN AGENT THAT DECREASES CHOLESTEROL | |
| ES2726401T3 (en) | Use of HDAC inhibitors for the treatment of bone destruction | |
| CA2347330A1 (en) | Liquid injectable formulation of disodium pamidronate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |